235 related articles for article (PubMed ID: 33772730)
21. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
23. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
25. Histologic transformation of lung cancer during pembrolizumab therapy: A case report.
Si X; You Y; Zhang X; Wang H; Wang M; Zhang L
Thorac Cancer; 2020 Mar; 11(3):793-796. PubMed ID: 31944570
[TBL] [Abstract][Full Text] [Related]
26. Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung.
Okauchi S; Sasatani Y; Shiozawa T; Yamada H; Miyazaki K; Takayashiki N; Satoh H
In Vivo; 2020; 34(3):1439-1443. PubMed ID: 32354943
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
Criss SD; Palazzo L; Watson TR; Paquette AM; Sigel K; Wisnivesky J; Kong CY
PLoS One; 2020; 15(1):e0228288. PubMed ID: 31995619
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Theelen WSME; Chen D; Verma V; Hobbs BP; Peulen HMU; Aerts JGJV; Bahce I; Niemeijer ALN; Chang JY; de Groot PM; Nguyen QN; Comeaux NI; Simon GR; Skoulidis F; Lin SH; He K; Patel R; Heymach J; Baas P; Welsh JW
Lancet Respir Med; 2021 May; 9(5):467-475. PubMed ID: 33096027
[TBL] [Abstract][Full Text] [Related]
29. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab.
Goda S; Tsuji T; Matsumoto Y; Shiotsu S; Tanaka S; Suga Y; Fujii H; Matsuyama A; Omura A; Yuba T; Takumi C; Hiraoka N
Curr Probl Cancer; 2021 Jun; 45(3):100686. PubMed ID: 33293197
[TBL] [Abstract][Full Text] [Related]
30. Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma.
Matsuo T; Tanaka T; Fujii N
J Clin Exp Hematop; 2017; 56(3):170-175. PubMed ID: 28331132
[TBL] [Abstract][Full Text] [Related]
31. Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab.
Takamori S; Furubayashi N; Taguchi K; Matsubara T; Fujishita T; Ito K; Yamaguchi M; Toyozawa R; Seto T; Negishi T; Nakamura M; Okamoto T
Thorac Cancer; 2021 Jul; 12(14):2122-2125. PubMed ID: 34002950
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
33. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.
Huang HH; Wen YC; Chen HM; Hsiao FY; Ko BS
Cancer Med; 2018 Aug; 7(8):3582-3591. PubMed ID: 30009424
[TBL] [Abstract][Full Text] [Related]
34. A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
Solal-Céligny P; Leconte P; Bardet A; Hernandez J; Troussard X
Br J Haematol; 2018 Jan; 180(2):217-223. PubMed ID: 29230799
[TBL] [Abstract][Full Text] [Related]
35. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.
Takada K; Sugita S; Murase K; Kikuchi T; Oomori G; Ito R; Hayasaka N; Miyanishi K; Iyama S; Ikeda H; Kobune M; Emori M; Kato J; Hasegawa T
Thorac Cancer; 2019 Dec; 10(12):2312-2315. PubMed ID: 31617320
[TBL] [Abstract][Full Text] [Related]
36. [Follicular (nodular) non Hodgkin's lymphoma of tonsil--case report].
Osuch-Wójcikiewicz E; Rzepakowska A; Bruzgielewicz A; Wieczorek J
Otolaryngol Pol; 2007; 61(2):203-6. PubMed ID: 17668812
[TBL] [Abstract][Full Text] [Related]
37. Follicular lymphoma-related colitis resembling ulcerative colitis.
Zenda T; Nakagawa N; Maruyama H; Endo T; Higashi K; Yamamoto J; Komai K; Watanabe K; Araki I
Clin J Gastroenterol; 2017 Apr; 10(2):147-153. PubMed ID: 28013449
[TBL] [Abstract][Full Text] [Related]
38. Antibody Therapy Maintenance in Follicular Lymphoma.
Golfier C; Salles G
Hematol Oncol Clin North Am; 2020 Aug; 34(4):689-699. PubMed ID: 32586574
[TBL] [Abstract][Full Text] [Related]
39. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
Peng TR; Wu TW
Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
[No Abstract] [Full Text] [Related]
40. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Barta SK; Zain J; MacFarlane AW; Smith SM; Ruan J; Fung HC; Tan CR; Yang Y; Alpaugh RK; Dulaimi E; Ross EA; Campbell KS; Khan N; Siddharta R; Fowler NH; Fisher RI; Oki Y
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):356-364.e3. PubMed ID: 31029646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]